David Michael
Managing Partner @ Anzu Partners
San Diego, United States
David Michael is a Series A investor at Anzu Partners in San Diego focused on Life Science and Biotechnology. David Michael is based out of San Diego, California and is the Managing Partner of Anzu Partners. David previously worked at The Boston Consulting Group as a Senior Partner. David Michael attended the Stanford University. David Michael has been Awarded school’s highest honor, the Ernest Arbuckle Award.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 70%
Last updated:
For AI agents: llms.txt
Industries David Michael invests in
Stages David Michael invests in
Countries David Michael invests in
Investment Focus
Industry
- Life Science 2 (20%)
- Biotechnology 2 (20%)
- Manufacturing 2 (20%)
- Laser 1 (10%)
- Energy 1 (10%)
Stage
- Series A 2 (20%)
- Venture - Series Unknown 2 (20%)
- Series B 1 (10%)
- Series C 1 (10%)
- Funding Round 1 (10%)
Country
- United States 3 (30%)
- Canada 1 (10%)
- Singapore 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
e-Zinc
|
Founded in 2012, e-Zinc is a Toronto, Canada, based corporation that has developed a breakthrough electrochemical technology for storing energy in zinc metal. This low-cost, flexible, and long-duration energy storage solution will provide the platform for the world’s energy markets to be fully powered by renewable energy, enabling a zero-carbonenergy future. | $31M / Series A / Jun 27, 2024 | |
TeraPore Technologies
|
TeraPore's cutting edge technology facilitates rapid and efficient purification of biological fluids. Combining uniform pores with large pore densities enables purification of high-value products with fast processing times. Please contact us for more information. | $10M / Venture - Series Unknown / Mar 02, 2023 | |
ImmunoScape
|
ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, andvisualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. | $14M / Venture - Series Unknown / Sep 20, 2022 | |
|
e-Zinc
|
Founded in 2012, e-Zinc is a Toronto, Canada, based corporation that has developed a breakthrough electrochemical technology for storing energy in zinc metal. This low-cost, flexible, and long-duration energy storage solution will provide the platform for the world’s energy markets to be fully powered by renewable energy, enabling a zero-carbonenergy future. | $25M / Series A / Apr 07, 2022 | |
NUBURU
|
NUBURU is disrupting the world's battery manufacturing, cell phone manufacturing, and e-mobility markets by providing the best in class technology for welding copper, aluminum and dissimilar metals. The disruptive performance of NUBURU's lasers has been validated by customers worldwide. It has invested in automated manufacturing inanticipation of the large demand from these rapidly growing market segments. NUBURU is currently in fund raising mode, seeking mezzanine funding for expanding manufacturing, sales, and marketing and operation organizations. The company blue laser technology breaks new ground—available as either a standard AO laser or high-brightness MISAKI laser by enabling radical gains in speed and quality in existing metal processes, as well as also unlocking a path to new designs for both conventional laser-metal machining and additive manufacturing (3D printing). | $5.6M / Private Equity / Jan 26, 2022 | |
InterVenn
|
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum orplasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.It was founded in 2017 and headquartered in Redwood City, California. | $201M / Series C / Aug 02, 2021 | |
|
ImmunoScape
|
ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, andvisualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. | $14M / Venture - Series Unknown / Apr 14, 2021 | |
|
InterVenn
|
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum orplasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.It was founded in 2017 and headquartered in Redwood City, California. | $34M / Series B / Nov 16, 2020 | |
|
ImmunoScape
|
ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, andvisualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. | $11M / Aug 12, 2020 | |
|
TeraPore Technologies
|
TeraPore's cutting edge technology facilitates rapid and efficient purification of biological fluids. Combining uniform pores with large pore densities enables purification of high-value products with fast processing times. Please contact us for more information. | $6M / Series A / Mar 06, 2018 |
Co-Investors
About Anzu Partners
Anzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industry. Anzu's portfolio support platform is dedicated to drive results beyond our initial investment and establish long-term relationships. We team with entrepreneurs to develop and commercializetechnological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. .Co-founders Whitney Haring-Smith, David Michael, and David Seldin launched the firm in 2014 in Washington, District of Columbia.
Anzu Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Cathryn Stickel
Director, Talent Management and Organizational Development
|
|||
|
Christine Fitzgerald
Senior Accountant
|
|||
|
David Michael
Managing Partner
|
|||
David Seldin
Managing Partner and Co-Founder
|
|||
Debrah Herman
Chief Financial Officer and Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Michael invest in?
David Michael invests primarily in Life Science, Biotechnology and Manufacturing startups, most often at Series A and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did David Michael last invest?
The most recent investment recorded for David Michael closed in Jun 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
